15 February 2022 | GMT (UTC+0)
Advances in Targeted Protein Degradation in target validation, therapeutics development and translation in the clinic.
The programme brings together world leaders from pharmaceutical and biotechnology companies as well as academic institutions to discuss the latest in Targeted Protein Degradation and PROTAC innovation
Full Registration is now open for Virtual Symposium: Targeted Protein Degradation & PROTAC. Please click the button below to register for this event.
Our LinkedIn group aims to foster discussion and collaboration between experts working in pathology, biomarker development and translational research.
Attendees representing global pharmaceutical organisations, leading biotech companies, internationally renowned academic and healthcare institutions discuss the latest in Targeted Protein Degradation and PROTAC innovation
Day One: 16 February
Day Two: 17 February
The Symposium brings together a panel of prominent leaders, engineers and scientists sharing new case studies, innovative data and industry outlook for the future
Below are speakers from 2021’s Targeted Protein Degradation & PROTAC Virtual Symposium
CeMM Research Centre for Molecular Medicine
Almac Discovery Ltd
PhoreMost
Cullgen
Pfizer
Scripps Research
University of California
Amphista Therapeutics Limited
University of Torino
Harvard Medical School
NYU
Kymera Therapeutics
Networking and knowledge Sharing is at the heart of what we do. Alongside the innovative programme, attendees can engage in a variety of Series features and make the most of participation in a range of virtual, remote experiences.
We produce cutting edge congresses and summits for the Life Sciences Industry, bringing together industry leaders and solution providers at a senior level, creating the opportunity to partner, network and knowledge share.
Syngene International Ltd. (BSE: 539268, NSE: SYNGENE, ISIN: INE398R01022) is an integrated contract research, development and manufacturing services company serving the global pharma, biotech, nutrition, animal health, consumer goods and specialty chemical sectors.
Our 4200 scientists have both the skills and the capability to deliver great science, ensure robust data management, IP security and quality manufacturing, at speed, to improve time-to-market and lower the cost of innovation.
With 1.9 Mn sq ft of specialist discovery, development and manufacturing facilities, Syngene offers dedicated research facilities for Amgen, Baxter, Bristol-Myers Squibb and Herbalife. We also work with biotech companies pursuing leading edge science, and MNCs including GSK and Merck KGaA.
We at Syngene have also gained considerable experience in Protein Degradation in recent years. We currently have a team of 130 FTEs working on the synthesis of PROTACS for various clients, and we have been able to advance several drug candidates to LO and even candidate delivery stage.
BioTheryX is a clinical-stage biopharmaceutical company focused on restoring protein homeostasis, including protein degradation and modulation, and multi-kinase inhibition to develop treatments intended to extend and improve the quality-of-life of patients with life-threatening diseases. Our principal technology platform centers on targeted protein degradation, PHM® ‘molecular glues’, that enable the design of small molecules to regulate protein equilibrium. This technology is designed to utilize the body’s own protein disposal system to selectively degrade and remove disease-causing proteins. It has potential applicability to a broad range of diseases, including targets that have to date been considered ‘undruggable’
WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical, biotech and medical device industries worldwide to advance discoveries and deliver groundbreaking treatments to patients. As an innovation-driven and customer-focused company, WuXi AppTec helps our partners improve the productivity of advancing healthcare products through cost-effective and efficient, socially responsible and sustainable solutions. With industry-leading capabilities such as R&D and manufacturing for small molecule drugs, cell and gene therapies, and testing for medical devices, WuXi AppTec’s open-access platform is enabling more than 4,100 collaborators from over 30 countries to improve the health of those in need – and to realize our vision that “every drug can be made and every disease can be treated.”
Over the last five years we have built a comprehensive platform for discovery and characterisation of bifunctional molecules, from initial hit finding activities, through characterisation with biophysical techniques and structural biology, and into in vitro and in vivo functional characterisation and DMPK. This platform is supported by several teams of synthetic organic chemists working across all classes of ligases, ligand and linker chemistries and supporting both optimisation and manufacturing activities.
